{"entity":{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","aka":[],"tldr":"Endpoints News is the fastest read on what biotech and pharma are doing in oncology, deal by deal.","summary":"Endpoints News covers the biopharma industry: deals, readouts, regulatory decisions and executive moves, and it is the fastest read on what biotech and pharma are doing in oncology, deal by deal. It sends daily newsletters and is particularly strong on China-out deals and on ADC and bispecific deal flow. Access is freemium with a premium subscription. On OnCo it is listed as a source with the tags source and news, read for the industry side of oncology.","asOf":"2026-09-08","links":[{"label":"Endpoints News","url":"https://endpoints.news/"}],"tags":["source","news"],"related":["src-biocentury","src-evaluate"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://endpoints.news/","holds":"Biopharma industry news: deals, readouts, regulatory decisions, executive moves.","license":"Freemium; premium subscription","maintainer":"Endpoints News"},"route":"/collections/src-endpoints-news/","neighbours":{"collection":[{"id":"src-biocentury","kind":"collection","name":"BioCentury","route":"/collections/src-biocentury/"},{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/"}],"company":[{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/"},{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/"},{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/"}]}}